A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma von Yee, Andrew J, Nadeem, Omar, Rosenblatt, Jacalyn, Bianchi, Giada, O'Donnell, Elizabeth, Branagan, Andrew R., Harrington, Cynthia C., Agyemang, Emerentia A., Gammon, Marilyn T., Lively, Kathleen J., Packer, Lisette A., Bernstein, Zachary S., Lyons, Rebecca T., Riadi, Manal, Rowell, Sean M., McVey, Cailin, Goguen, Amy C., Horick, Nora K., Richardson, Paul G., Raje, Noopur S.

Volltext

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) von O'Donnell, Elizabeth K., Mo, Clifton C, Nadeem, Omar, Yee, Andrew J., Branagan, Andrew R., Laubach, Jacob, Gammon, Marilyn T., Lively, Kathleen J., Packer, Lisette, Harrington, Cynthia C., Agyemang, Emerentia, Rosenblatt, Jacalyn, Horick, Nora K., Richardson, Paul G., Raje, Noopur

Volltext

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia von Branagan, Andrew R., Lei, Matthew M, Mo, Clifton C, Yee, Andrew J., O'Donnell, Elizabeth K., Castillo, Jorge J., Nadeem, Omar, Raje, Noopur, Treon, Steven P, Richardson, Paul G., Nakamoto-Matsubara, Rie, Meid, Kirsten, Bernstein, Zachary S., Lyons, Rebecca T., Verma, Rakesh, Hunter, Zachary R, Guerrera, Maria Luisa, Flynn, Catherine A., Burke, Jill N., Harrington, Cynthia C., Agyemang, Emerentia, Gammon, Marilyn T., Lively, Kathleen J., Packer, Lisette, Horick, Nora K., Sarosiek, Shayna

Volltext